Delivery Order SPE2DB22D2211-SPE2DB25FSBPS
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order on July 25, 2025, for supply of Zepbound (tirzepatide) 10 mg/0.5 mL pens with a ceiling value of $1,143.87. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of July 28, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $4,575.48 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pre-filled pens. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and carries an ultimate completion date of July 28, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary headquarters and...
- The Defense Logistics Agency awarded a $19,064.54 delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injections on July 25, 2025. This firm fixed-price delivery order, with an ultimate completion date of July 28, 2025, was competitively awarded with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary...
- The Defense Logistics Agency awarded a $1,143.87 delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pens on July 18, 2025, with completion targeted for July 21, 2025. This firm fixed-price contract represents a competitively awarded, non-set-aside procurement executed by the prime contractor's corporate office located in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency has awarded a delivery order valued at $4,397.68 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens in 0.5 mL quantities. This firm fixed-price contract, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, represents a non-competitive, competitively-awarded delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Zepbound 5 mg/0.5 ml pen injectors with a ceiling value of $3,812.90. This is a firm fixed-price delivery order with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,596.50 to AmerisourceBergen Drug Corp for Zepbound (tirzepatide) 10 mg/0.5 mL pen injectors on July 25, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation, with an ultimate completion date of July 28, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Zepbound 10 mg/0.5 ml pens with a ceiling value of $1,525.20. This competitive award, utilizing firm fixed pricing with no set-aside designation, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's headquarters location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $29,311.50 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on July 21, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside delivery order with an ultimate completion date of July 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $9,687.82 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pens on July 21, 2025, with an ultimate completion date of July 22, 2025. This is a firm fixed price contract with no set-aside designation, awarded through open competition. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, which serves as the company's corporate headquarters and primary distribution hub...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSBPSDelivery Order
The Defense Logistics Agency awarded a delivery order valued at approximately $43.3K to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999.9M through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, functions as a critical vendor for federal medical procurement through the DLA's Medical Supply Chain. The company's extensive portfolio of federal contract awards demonstrates its capability to supply a broad range of pharmaceutical products and medical supplies, including specialty medications, vaccines, and medical devices across multiple therapeutic domains. This particular delivery order for Zepbound—a GLP-1 receptor agonist indicated for weight management—supports the Department of Defense's healthcare requirements and reflects the company's ongoing role in fulfilling federal pharmaceutical supply needs through competitive, firm fixed-price delivery mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $43.3k | 7/25/25 |